Patents Assigned to BUCK INSTITUTE FOR RESEARCH ON AGING
-
Patent number: 9855266Abstract: Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.Type: GrantFiled: March 23, 2017Date of Patent: January 2, 2018Assignees: Unity Biotechnology, Inc., Buck Institute for Research on Aging, Mayo Foundation for Medical Education and Research, The John Hopkins UniversityInventors: Remi-Martin Laberge, Judith Campisi, Albert Davalos, Marco Demaria, Nathaniel David, Alain Philippe Vasserot, James L. Kirkland, Tamar Tchkonia, Jennifer Elisseeff, Chaekyu Kim, Okhee Jeon, Yi Zhu
-
Patent number: 9849128Abstract: Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.Type: GrantFiled: March 10, 2017Date of Patent: December 26, 2017Assignees: Unity Biotechnology, Inc., Buck Institute for Research on Aging, Mayo Foundation for Medical Education and Research, The John Hopkins UniversityInventors: Remi-Martin Laberge, Judith Campisi, Albert Davalos, Marco Demaria, Nathaniel David, Alain Philippe Vasserot, James L. Kirkland, Tamar Tchkonia, Yi Zhu, Jennifer Elisseeff, Chaekyu Kim, Okhee Jeon
-
Patent number: 9617514Abstract: In certain embodiments methods are provided for inducing and/or restoring and/or maintaining a non-senescent phenotype, or aspects thereof (e.g., proliferative capacity and/or pluripotency) in a mammalian cell. The methods typically involve reducing the level or activity of SINE/Alu retrotransposon transcripts in the cell in an amount sufficient to induce or restore proliferative capacity and/or pluripotency to said mammalian cell.Type: GrantFiled: October 20, 2011Date of Patent: April 11, 2017Assignee: BUCK INSTITUTE FOR RESEARCH ON AGINGInventor: Victoria V. Lunyak
-
Patent number: 9605001Abstract: The present invention relates to production of polyketides and other natural products and to libraries of compounds and individual novel compounds. One important area is the isolation and potential use of novel FKBP-ligand analogues and host cells that produce these compounds. The invention is particularly concerned with methods for the efficient transformation of strains that produce FKBP analogues and recombinant cells in which cloned genes or gene cassettes are expressed to generate novel compounds such as polyketide (especially rapamycin) FKBP-ligand analogues, and to processes for their preparation, and to means employed therein (e.g. nucleic acids, vectors, gene cassettes and genetically modified strains).Type: GrantFiled: March 2, 2015Date of Patent: March 28, 2017Assignee: Buck Institute for Research On AgingInventors: Matthew Alan Gregory, Steven James Moss
-
Patent number: 9534016Abstract: In certain embodiments compositions are provided that comprise a pentapeptide comprising the formula: C1-X2-X3-X4-C5 where C1 and C5 are independently selected cysteines or cysteine analogues, or other amino acids with sidechains suitable for cyclization, where the cysteines or cysteine analogs are attached to each other by a linkage that does not comprise X2, X3, and X4; where X2, X3, and X4 are independently selected amino acids; and the peptide, when administered to a cell alters APP signaling and/or switches APP processing from aberrant to normal. The compositions mitigate amyloid plaque formation.Type: GrantFiled: November 27, 2012Date of Patent: January 3, 2017Assignee: BUCK INSTITUTE FOR RESEARCH ON AGINGInventors: Varghese John, Clare Peters-Libeu, Dale E. Bredesen
-
Patent number: 9382266Abstract: There is provided inter alia a compound of formula (I) or a pharmaceutically acceptable salt thereof and its use in therapy.Type: GrantFiled: December 21, 2012Date of Patent: July 5, 2016Assignee: BUCK INSTITUTE FOR RESEARCH ON AGINGInventors: Matthew Alan Gregory, Steven James Moss, Barrie Wilkinson
-
Publication number: 20160038552Abstract: The invention generally provides supplements and methods of using the same to improve cognitive functions such as learning, memory, concentration, focus, attention, and mood.Type: ApplicationFiled: March 13, 2014Publication date: February 11, 2016Applicant: Buck Institute for Research on AgingInventors: Dale E. BREDESEN, Varghese JOHN
-
Patent number: 9245290Abstract: This invention provides novel caspase inhibitors useful for prophylaxis or treatment of a number of pathologies, including, for example, Huntington's disease. In certain embodiments the inhibitors include inhibitors of casepase-3 and/or casepase-6.Type: GrantFiled: August 15, 2013Date of Patent: January 26, 2016Assignees: Buck Institute for Research on Aging, The Regents of the University of CaliforniaInventors: Lisa M. Ellerby, Jonathan A. Ellman, Melissa J. Leyva
-
Patent number: 9040259Abstract: The present invention relates to production of polyketides and other natural products and to libraries of compounds and individual novel compounds. One important area is the isolation and potential use of novel FKBP-ligand analogs and host cells that produce these compounds. The invention is particularly concerned with methods for the efficient transformation of strains that produce FKBP analogs and recombinant cells in which cloned genes or gene cassettes are expressed to generate novel compounds such as polyketide (especially rapamycin) FKBP-ligand analogs, and to processes for their preparation, and to means employed therein (e.g. nucleic acids, vectors, gene cassettes and genetically modified strains).Type: GrantFiled: March 11, 2011Date of Patent: May 26, 2015Assignee: Buck Institute for Research on AgingInventors: Matthew Alan Gregory, Sabine Gaisser, Hrvoje Petkovic, Steven Moss
-
Patent number: 8981066Abstract: This invention pertains to markers of cellular senescence. In particular methylation of histone H1 (or isoforms thereof) at residue 172 and/or at residue 180 is a marker of cellular senescence. Antibodies specific to histone H1 (or isoforms thereof) methylated at residue 172 and/or at residue 180 are provided.Type: GrantFiled: August 23, 2012Date of Patent: March 17, 2015Assignee: Buck Institute for Research on AgingInventor: Victoria V. Lunyak
-
Publication number: 20140371283Abstract: In certain embodiments hydantoin compounds are provided herein that are effective to inhibit BACE activity against APP. Without being bound to a particular theory, it is believed the activity of the hydantoins identified herein appears to be associated with binding to BACE and/or to APP particularly when these moieties form a BACE/APP complex. Accordingly, it is believed the compounds described herein represent a new class of compounds designated herein as APP-Binding-BACE Inhibitors (ABBIs) and provide a new mechanism to modulate APP processing. The hydantoins described herein appear to show improved brain permeability and functional BACE inhibition.Type: ApplicationFiled: February 12, 2014Publication date: December 18, 2014Applicant: Buck Institute for Research on AgingInventors: VARGHESE JOHN, Dale E. BREDESEN
-
Publication number: 20140364451Abstract: In various embodiments, compositions and methods are provided for treatment and/or prevention of amyloidogenic diseases. In certain embodiments, the methods entail administering an effective amount of a tropinol ester to a subject in need thereof for prophylactic or therapeutic effect. The methods are particularly useful for prophylactic and therapeutic treatment of Alzheimer's disease. In certain embodiments, methods of reducing the risk, lessening the severity, or delaying the progression or onset of a disease characterized by beta-amyloid deposits in the brain of a mammal are also provided. In certain embodiments, methods of directly or indirectly inhibiting the C-terminal cleavage of APP resulting in the formation of APP-C31 peptide and APPneo (AP-P664) in a mammal are provided.Type: ApplicationFiled: August 1, 2012Publication date: December 11, 2014Applicant: BUCK INSTITUTE FOR RESEARCH ON AGINGInventors: Varghese John, Dale E. Bredesen
-
COMPOUNDS AND METHODS FOR MODULATING MITOCHONDRIAL METABOLISM AND REACTIVE OXYGEN SPECIES PRODUCTION
Publication number: 20140128352Abstract: Compounds that modulate mitochondrial reactive oxygen species (ROS) production are provided. The compounds may modulate ROS production at defined sites without also altering energy production. Methods of using and identifying such compounds are also provided.Type: ApplicationFiled: September 20, 2013Publication date: May 8, 2014Applicant: Buck Institute for Research on AgingInventors: Martin D. Brand, Adam Orr -
Publication number: 20140011847Abstract: This invention provides novel caspase inhibitors useful for prophylaxis or treatment of a number of pathologies, including, for example, Huntington's disease. In certain embodiments the inhibitors include inhibitors of casepase-3 and/or casepase-6.Type: ApplicationFiled: August 15, 2013Publication date: January 9, 2014Applicants: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, BUCK INSTITUTE FOR RESEARCH ON AGINGInventors: Lisa M. ELLERBY, Jonathan A. ELLMAN, Melissa J. LEYVA
-
Publication number: 20130344603Abstract: In certain embodiments methods are provided for inducing and/or restoring and/or maintaining a non-senescent phenotype, or aspects thereof (e.g., proliferative capacity and/or pluripotency) in a mammalian cell. The methods typically involve reducing the level or activity of SINE/Alu retrotransposon transcripts in the cell in an amount sufficient to induce or restore proliferative capacity and/or pluripotency to said mammalian cell.Type: ApplicationFiled: October 20, 2011Publication date: December 26, 2013Applicant: BUCK INSTITUTE FOR RESEARCH ON AGINGInventor: Victoria V. Lunyak
-
Patent number: 8518942Abstract: This invention provides novel caspase inhibitors useful for prophylaxis or treatment of a number of pathologies, including, for example, Huntington's disease. In certain embodiments the inhibitors include inhibitors of casepase-3 and/or casepase-6.Type: GrantFiled: August 6, 2009Date of Patent: August 27, 2013Assignees: Buck Institute for Research on Aging, The Regents of the University of CaliforniaInventors: Lisa M. Ellerby, Jonathan A. Ellman, Melissa J. Leyva
-
Publication number: 20130065254Abstract: This invention pertains to markers of cellular senescence. In particular methylation of histone H1 (or isoforms thereof) at residue 172 and/or at residue 180 is a marker of cellular senescence. Antibodies specific to histone H1 (or isoforms thereof) methylated at residue 172 and/or at residue 180 are provided.Type: ApplicationFiled: August 23, 2012Publication date: March 14, 2013Applicant: BUCK INSTITUTE FOR RESEARCH ON AGINGInventor: VICTORIA V. LUNYAK
-
Publication number: 20130017274Abstract: In various embodiments methods of delaying the onset of and/or mitigating the severity of one or more symptoms of Parkinson's disease in a mammal are provided. In certain embodiments the methods involve administering to a mammal diagnosed as having or as at risk for Parkinson's disease a chronic low dose of lithium (e.g., a subtherapeutic dose). In certain embodiments the low dose lithium is administered in conjunction with another agent (e.g., L-DOPA).Type: ApplicationFiled: March 16, 2012Publication date: January 17, 2013Applicant: BUCK INSTITUTE FOR RESEARCH ON AGINGInventors: JULIE K. ANDERSEN, HWAN KIM
-
Publication number: 20120244567Abstract: Methods of culturing embryonic stem cells in a format suitable for high-throughput screening (HTS) are provided. In addition compounds that show differential cytotoxic/protective activity on embryonic stem cells (ESCs) and neurological stem cells (NSCs) are provided.Type: ApplicationFiled: September 3, 2010Publication date: September 27, 2012Applicant: BUCK INSTITUTE FOR RESEARCH ON AGINGInventor: Xianmin Zeng
-
Publication number: 20120129834Abstract: Methods are provided for the treatment and/or prophylaxis of Huntington's disease. In various embodiments the methods involve administration of one or more serotonin receptor antagonists. In certain embodiments the serotonin receptor antagonists include, but are not limited to loxapine, and/or a loxapine analogue, and/or cyproheptadine, and/or a cyproheptadine analogue (e.g., pizotifen).Type: ApplicationFiled: September 16, 2011Publication date: May 24, 2012Applicant: BUCK INSTITUTE FOR RESEARCH ON AGINGInventors: ROBERT HUGHES, LISA ELLERBY